Stock 42C IX BIOPHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases iX Biopharma Ltd.

Equities

42C

SG1BD9000009

Market Closed - Singapore S.E.
Other stock markets
 04:45:15 2024-05-02 am EDT 		5-day change 1st Jan Change
0.047 SGD +9.30% Intraday chart for iX Biopharma Ltd. +11.90% +4.44%
Mar. 12 Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer MT
Mar. 12 IX Biopharma Introduces New Sublingual Wafer MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IX Biopharma : Sustainability Report
PU
General Announcement::CHANGES IN THE COMPOSITION OF THE BOARD AND BOARD COMMITTEES
PU
General Announcement::Minutes of Annual General Meeting held on 15 October 2021
PU
General Announcement::iX Biopharma Expands Nutraceuticals Portfolio With Innovative Anti-Aging Sublingual NAD+ Product
PU
General Announcement::iX Biopharma Signs Wafesil Licensing Agreement with China Resources Pharmaceutical Commercial Group
PU
IX Biopharma : 2H (Unaudited)
PU
Employee Stock Option/ Share Scheme::GRANT OF SHARE OPTION PURSUANT TO iX EMPLOYEE SHARE OPTION SCHEME
PU
IX Biopharma : The Board of Directors refers to the announcement dated 30 June 2021 in relation to, amongst others, the lodgement of the offer information statement in connection with the proposed renounceable non-underwritten rights issues of up to 48,814,711 new ordinary shares in the capital of the Company ("Offer Information Statement").
PU
General Announcement::Press Release: iX Biopharma Commences Supply of Medicinal Cannabis Wafers to Brazil
PU
REPL::Rights::Voluntary
PU
IX Biopharma : is pleased to announce that it will supply its novel Wafermine sublingual ketamine wafers in a pilot study funded by Chris O’Brien Lifehouse, one of Australia’s leading comprehensive cancer hospitals in Camperdown, Sydney. The study will evaluate the efficacy, acceptability, safety and tolerability of Wafermine administered as a first-line treatment for patients with advanced cancer suffering from moderate to severe pain.
PU
IX Biopharma : Expands Wafer Production Capacity to Meet Growing Demand
PU
IX Biopharma : is pleased to announce that the United States Food and Drug Administration (US FDA) has granted the Company an orphan drug designation for treatment of patients with Complex Regional Pain Syndrome (CRPS) with ketamine.
PU
IX Biopharma : enters cooperation deal with China Resources Pharmaceutical Commercial Group
AQ
IX Biopharma: Enters Strategic Cooperation Framework Agreement With China Resources Pharmaceutical Commercial Group.
AQ
IX Biopharma : is pleased to announce it has entered into a cooperation deal with China Resources Pharmaceutical Commercial Group.
PU
IX Biopharma : has reported its first half results for the financial year as of 31 December 2020.
PU
IX Biopharma : receives positive EMA Scientific Advice for Wafermine
AQ
IX Biopharma : is pleased to announce that it has received positive feedback from the European Medicines Agency (EMA) in its scientific advice to the Company regarding its Phase 3 clinical development programme for Wafermine, its sublingual ketamine wafer, for registration in Europe.
PU
IX Biopharma : obtains approval and registration of Silcap for the treatment of male erectile dysfunction in Singapore
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 42C Stock
  4. News iX Biopharma Ltd.
  5. Press Releases